Harbin Jixianglong Biotech Co. Recalls

2 recalls found for Harbin Jixianglong Biotech Co.. Check if any of your products are affected.

HIGHFDA DRUG

Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall (2026)

Harbin Jixianglong Biotech Co. recalled semaglutide for Rx compounding use distributed nationwide to healthcare providers in the United States. The recall cites CGMP deviations and failure to complete process validation and bacterial endotoxin method validation before distribution. Healthcare providers and patients should stop using this product immediately and contact the manufacturer or their CL

Harbin Jixianglong Biotech Co.
CGMP Deviations
Read more
HIGHFDA DRUG

Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall 2026 — 6 Packaging Sizes

Harbin Jixianglong Biotech Co. recalled Semaglutide for Rx compounding use nationwide in the United States. The recall cites CGMP deviations and failure to complete endotoxin validation before distribution. Healthcare providers and patients should stop using the product immediately and contact the company or a healthcare provider for guidance via email.

Harbin Jixianglong Biotech Co.
CGMP Deviations
Read more

Brand Statistics

Total Recalls
2
Pages
1